NTI164 in children with paediatric acute-onset neuropsychiatric syndrome

Phase 2, open-label, single-arm trial of NTI164 in pediatric acute-onset neuropsychiatric syndrome (PANS), sponsored by Fenix Innovation Group. Primary endpoints: Change in Revised Children's Anxiety and Depression Scale Parent Version emotional symptoms score at Week 52 and Change in Clinical Global Impression Scale at Week 52. Started May 2023; status: active, not recruiting.